NOVATO, Calif., April 7, 2010 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), today announced the engagement of The Trout Group LLC, a leading New York-based investor relations and strategic advisory firm. The Trout Group will work with Raptor to facilitate the Company's exposure to the international capital markets and coordinate their communications with investors worldwide. With extensive institutional investor relationships in the United States and Europe, The Trout Group provides strategic advisory and investor relations services exclusively to Life Sciences companies.
"Over the last 4 years, Raptor has grown from an angel funded start-up with exciting preclinical programs to a later-stage NASDAQ-listed biotechnology company with what we believe is a solid clinical pipeline. The Company's lead clinical program, DR Cysteamine for the potential treatment of cystinosis, will soon enter its final clinical trial and may be ready for commercial launch in 2011," stated Christopher M. Starr, Ph.D., Raptor's chief executive officer. "With our existing investor base spread throughout Europe, Canada, Australia and the U.S., the global capabilities of The Trout Group will enable us to consolidate our investor communication and outreach. Their experience in emerging life science companies and orphan product clinical programs is a perfect fit with our current needs and will be a tremendous asset to us as we complete the final clinical phase of our cystinosis program and prepare for a potential commercial launch next year."
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development designed to potentially treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), aldehyde dehydrogenase ("ALDH2") deficiency, and a non-opioid solution designed to potentially treat chronic pain.
Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7180
FORWARD LOOKING STATEMENTS
This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that The Trout Group will be able to effectively facilitate Raptor's exposure to international capital markets and coordinate communications with investors worldwide; that DR Cysteamine for the potential treatment of cystinosis, will soon enter its final clinical trial and may be ready for commercial launch in 2011; that The Trout Group will enable Raptor to consolidate its investor communication and outreach and will be a tremendous asset to Raptor; that Raptor will complete the final clinical phase of its cystinosis program and prepare for a potential commercial launch next year; and Raptor's ability to successfully develop any of its product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results to be materially different from these forward-looking statements. Factors which may significantly change or prevent the Company's forward looking statements from fruition include that Raptor may be unsuccessful in developing any products or acquiring products; that Raptor's technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; that Raptor is unable to retain or attract key employees whose knowledge is essential to the development of its products; that unforeseen scientific difficulties develop with the Company's process; that Raptor's patents are not sufficient to protect essential aspects of its technology; that competitors may invent better technology; that Raptor's products may not work as well as hoped or worse, that the Company's products may harm recipients; and that Raptor may not be able to raise sufficient funds for development or working capital. As well, Raptor's products may never develop into useful products and even if they do, they may not be approved for sale to the public. Raptor cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings from time to time with the Securities and Exchange Commission (the "SEC"), which Raptor strongly urges you to read and consider, including Raptor's current report on Form 8-K filed with the SEC on February 5, 2010; and Raptor's quarterly report on Form 10-Q/A filed with the SEC on January 15, 2010, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to Raptor or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in Raptor's reports filed with the SEC. Raptor expressly disclaims any intent or obligation to update any forward-looking statements.